These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 11526378)

  • 1. Multiple sclerosis: a two-stage disease.
    Steinman L
    Nat Immunol; 2001 Sep; 2(9):762-4. PubMed ID: 11526378
    [No Abstract]   [Full Text] [Related]  

  • 2. The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal.
    Lassmann H; Ransohoff RM
    Trends Immunol; 2004 Mar; 25(3):132-7. PubMed ID: 15036040
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating the evidence for multiple sclerosis as an autoimmune disease.
    Altmann D
    Arch Neurol; 2005 Apr; 62(4):688; author reply 688-9. PubMed ID: 15824275
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple sclerosis: is there neurodegeneration independent from inflammation?
    Lassmann H
    J Neurol Sci; 2007 Aug; 259(1-2):3-6. PubMed ID: 17367814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA; Kim E; Moodie J
    Int J Nanomedicine; 2006; 1(3):283-9. PubMed ID: 17717969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protecting axons in multiple sclerosis.
    Wilkins A; Scolding N
    Mult Scler; 2008 Sep; 14(8):1013-25. PubMed ID: 18632772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stress and disease progression in multiple sclerosis and its animal models.
    Gold SM; Heesen C
    Neuroimmunomodulation; 2006; 13(5-6):318-26. PubMed ID: 17709954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F; Kieseier BC
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract]   [Full Text] [Related]  

  • 9. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.
    Steinman L; Zamvil SS
    Trends Immunol; 2005 Nov; 26(11):565-71. PubMed ID: 16153891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroids treatment.
    Pozzilli C; Marinelli F; Romano S; Bagnato F
    J Neurol Sci; 2004 Aug; 223(1):47-51. PubMed ID: 15261560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological patterns identifying disease course and evolution in multiple sclerosis patients.
    Furlan R; Rovaris M; Martinelli Boneschi F; Khademi M; Bergami A; Gironi M; Deleidi M; Agosta F; Franciotta D; Scarpini E; Uccelli A; Zaffaroni M; Kurne A; Comi G; Olsson T; Filippi M; Martino G
    J Neuroimmunol; 2005 Aug; 165(1-2):192-200. PubMed ID: 15949850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of multiple sclerosis: where are we? Where should we go?
    Martin R; Stürzebecher CS; McFarland HF
    Nat Immunol; 2001 Sep; 2(9):785-8. PubMed ID: 11526386
    [No Abstract]   [Full Text] [Related]  

  • 13. New insights into adaptive immunity in chronic neuroinflammation.
    Siffrin V; Brandt AU; Herz J; Zipp F
    Adv Immunol; 2007; 96():1-40. PubMed ID: 17981203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degeneration versus autoimmunity in multiple sclerosis.
    Tsutsui S; Stys PK
    Ann Neurol; 2009 Dec; 66(6):711-3. PubMed ID: 20033985
    [No Abstract]   [Full Text] [Related]  

  • 15. Inflammation and degeneration in multiple sclerosis.
    Brück W; Stadelmann C
    Neurol Sci; 2003 Dec; 24 Suppl 5():S265-7. PubMed ID: 14652785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy.
    Vaknin-Dembinsky A; Weiner HL
    J Neurol Sci; 2007 Aug; 259(1-2):90-4. PubMed ID: 17521671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.
    Jeffery DR
    J Neurol Sci; 2004 Aug; 223(1):41-6. PubMed ID: 15261559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis].
    Mestre L; Correa F; Docagne F; Clemente D; Ortega-Gutiérrez S; Arévalo-Martín A; Molina-Holgado E; Borrell J; Guaza C
    Rev Neurol; 2006 Nov 1-15; 43(9):541-8. PubMed ID: 17072810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linkage between immunomodulation, neuroprotection and neurogenesis.
    Aharoni R; Arnon R
    Drug News Perspect; 2009; 22(6):301-12. PubMed ID: 19771319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.